It's been a while since the US FDA had a meeting of an Advisory Committee to discuss the future in the United States of the diabetes drug rosiglitazone (brand name Avandia), way back in July. Now it's the European's turn to shine the light on rosiglitazone and its troubled safety record:

* The BBC's Panorama show ("The world's longest running investigative TV show") is airing a program titled A Risk Worth Taking? on BBC One today (September 6). The program apparently implies that UK regulators...